SAVA – cassava sciences, inc. (US:NASDAQ)
Stock Stats
News
Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease
Cassava Sciences (NASDAQ:SAVA) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Cassava Announces Agreement to Settle Securities Class Action Litigation
Cassava Sciences rises 10% after market close on CEO stock buy [Seeking Alpha]
Form 8-K CASSAVA SCIENCES INC For: Dec 19
Form 8-K/A CASSAVA SCIENCES INC For: Oct 21
Form 8-K CASSAVA SCIENCES INC For: Dec 15
Form 8-K CASSAVA SCIENCES INC For: Dec 12
Form EFFECT CASSAVA SCIENCES INC
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.